12 completed, 2 active not recruiting, 1 not yet recruiting. 11 Phase 1, 3 Phase 3, 1 Phase 2.
By phase and status
Follow BMS-986278: new trials by email Literature Review of BMS-986278 trials Research Report on BMS-986278
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix .
Trial Phase Status Sponsor Enrollment Start Updated
Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis BMS-986278 - Pulmonary Fibrosis Phase 3 Not yet recruiting Bristol-Myers Squibb 2380 2026-12-16 2026-08-14 A Study to Evaluate the Effect of BMS-986278 on Cardiac Repolarization in Healthy Participants BMS-986278, Placebo, Moxifloxacin - Healthy Volunteers Phase 1 Completed Bristol-Myers Squibb 32 2026-02-19 2026-08-03 A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of BMS-986278 and the Effects of BMS-986278 on Cardiac Repolarization in Healthy Participants BMS-986278, Placebo, Moxifloxacin - Healthy Volunteers Phase 1 Completed Bristol-Myers Squibb 42 2025-02-10 2025-10-06 A Study to Evaluate BMS-986278 in Participants With Normal Renal Function, Severe Renal Impairment, or End-Stage Renal Disease on Intermittent Hemodialysis BMS-986278 - Kidney Failure, Chronic, Healthy Volunteers Phase 1 Completed Bristol-Myers Squibb 27 2024-12-07 2025-10-14 Study to Assess Drug Levels and Safety of BMS-986278 in Healthy Participants and Participants With Different Degrees of Hepatic Impairment BMS-986278 - Hepatic Impairment, Healthy Participants Phase 1 Completed Bristol-Myers Squibb 37 2024-06-10 2025-01-22 A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis BMS-986278, BMS-986278 Placebo - Progressive Pulmonary Fibrosis Phase 3 Active not recruiting Bristol-Myers Squibb 1057 2023-10-25 2026-04-23 A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis BMS-986278, BMS-986278 Placebo - Idiopathic Pulmonary Fibrosis Phase 3 Active not recruiting Bristol-Myers Squibb 1255 2023-09-14 2026-03-24 A Study to Investigate the Effects of BMS-986278 on Drospirenone and Ethinyl Estradiol Drug Levels in Healthy Female Participants BMS-986278, Drospirenone/Ethinyl Estradiol - Healthy Volunteers Phase 1 Completed Bristol-Myers Squibb 37 2023-08-18 2024-01-24 A Study to Assess the Effect of Multiple Doses of Itraconazole, Gemfibrozil, or Carbamazepine on BMS-986278 in Healthy Participants BMS-986278, Itraconazole, Gemfibrozil - Healthy Participants Phase 1 Completed Bristol-Myers Squibb 47 2023-07-12 2023-10-30 A Study to Evaluate the Drug Levels, Safety, and Tolerability of BMS-986278 in Healthy Chinese Participants BMS-986278, Placebo - Healthy Volunteers Phase 1 Completed Bristol-Myers Squibb 24 2023-03-29 2023-09-18 A Study Investigating the Safety, Tolerability, Drug Levels and Drug Effect of BMS-986278 in Healthy Adult Participants (Part 1) and Japanese Participants (Part 2) BMS-986278, Sildenafil, Placebo - Healthy Participants Phase 1 Completed Bristol-Myers Squibb 61 2023-01-03 2023-08-24 A Study Measuring the Effectiveness, Safety, and Tolerability of BMS-986278 in Participants With Lung Fibrosis BMS-986278 Placebo, BMS-986278 - Pulmonary Fibrosis Phase 2 Completed Bristol-Myers Squibb 403 2020-07-29 2026-02-03 A Study of the Pharmacokinetic Interaction Between Pirfenidone and BMS-986278 in Healthy Participants BMS-986278, Pirfenidone - Idiopathic Pulmonary Fibrosis (IPF) Phase 1 Completed Bristol-Myers Squibb 22 2019-05-10 2020-05-15 An Investigational Study of Experimental Medication BMS-986278 Given With the Antibiotic Rifampin in Healthy Participants BMS-986278, Rifampin - Healthy Participants Phase 1 Completed Bristol-Myers Squibb 39 2018-09-06 2019-06-12 A Study of Experimental Medication BMS-986278 Given to Healthy Participants BMS-986278, Placebo - Healthy Participants Phase 1 Completed Bristol-Myers Squibb 112 2018-02-07 2019-10-01
Conditions studied Idiopathic Pulmonary Fibrosis (6) · Pulmonary Fibrosis (5) · Lung Diseases, Interstitial (2) · Arthritis, Rheumatoid (1) · Connective Tissue Diseases (1) · Fibrosis (1) · Idiopathic Interstitial Pneumonias (1) · Kidney Failure, Chronic (1) · Liver Diseases (1) · Lymphoma, Follicular (1) · Renal Insufficiency (1) · Sarcoidosis (1) · Scleroderma, Diffuse (1)
Sponsors Bristol-Myers Squibb (15)
Countries United States (11) · Canada (6) · China (5) · United Kingdom (5) · Argentina (4) · Australia (4) · Belgium (4) · Brazil (4) · Chile (4) · France (4) · Germany (4) · Israel (4) · Italy (4) · Japan (4) · Mexico (4)
Results publications PMID 34709814 , PMID 34969771 , PMID 39393084 , PMID 40210090
NIH funding 2023 (2), 2017 (1), 2019 (1), 2025 (1)